Astellas Homepage | Astellas Innovation Management LLC

News

News / General News

Mar 28, 2019

Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer - Companies Plan to Submit Biologics License Application Later This Year –

News / General News

Mar 26, 2019

Astellas Presents Fezolinetant Phase 2b Clinical Trial Results at Endocrine Society’s Annual Meeting (ENDO) - Investigational compound fezolinetant reduced frequency and severity of vasomotor symptoms in postmenopausal women -

News / General News

Mar 18, 2019

Astellas Launches PROGRAF^® Granules (tacrolimus for oral suspension) in the U.S. for Pediatric Liver, Heart, and Kidney Transplant Patients

News / General News

Feb 20, 2019

Astellas and WiserCare Announce Collaboration to Improve Patient Experience - Joint Project Will Explore Enhancements to Patient Communication and Shared Decision-Making -

News / General News

Feb 11, 2019

Phase 3 ARCHES Trial Shows XTANDI^® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer

News / General News

Dec 20, 2018

Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI^® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer